1 Compared with the general population, patients with cancer are at increased risk of breakthrough SARS-CoV-2 infection and severe COVID-19. The growing number of US hospitals electing to remove masking requirements that had been in place to control COVID-19 has sparked some debate as to whether it is premature to remove masking mandates, particularly in higher-risk settings, such as hospitals. With the emergence of new, immune-evasive SARS-CoV-2 variants, many of which are anticipated to be resistant to monoclonal antibody treatments, strategies to prevent COVID-19 transmission should remain a high priority. In subgroup analyses by cancer site, COVID-19 mortality increased the most, by 38%, among patients with lymphoma during the winter Omicron period vs the wild-type period.Ĭonclusions and Relevance Findings of this cross-sectional study suggest that patients with cancer had a disparate burden of COVID-19 mortality during the winter Omicron wave compared with the general US population. In contrast, among the general public, the greatest number of COVID-19 deaths per month occurred during the wild-type period (n = 105 327), and at the peak of the winter Omicron period, there were 21% fewer COVID-19 deaths compared with the peak of the wild-type period. Among patients with cancer, the greatest number of COVID-19 deaths per month occurred during the winter Omicron period (n = 5958): at the peak of the winter Omicron period, there were 18% more deaths compared with the peak of the wild-type period. Results The sample included 34 350 patients with cancer (14 498 females and 19 852 males ) and 628 156 members of the general public (276 878 females and 351 278 males ) who died from COVID-19 when the wild-type (December 2020-February 2021), Delta (July 2021-November 2021), and winter Omicron (December 2021-February 2022) variants were predominant. Main Outcomes and Measures Number of COVID-19 deaths per month. Data were analyzed from July 21 through August 31, 2022.Įxposures Pandemic wave during which the wild-type variant (December 2020 to February 2021), Delta variant (July 2021 to November 2021), or Omicron variant (December 2021 to February 2022) was predominant. The number of deaths due to COVID-19 during the 2021 to 2022 winter Omicron surge was compared with deaths during the preceding year’s COVID-19 winter surge (when the wild-type SARS-CoV-2 variant was predominant) using mortality ratios. Objective To evaluate COVID-19 mortality among US patients with cancer compared with the general US population during different waves of the pandemic.ĭesign, Setting, and Participants This cross-sectional study used data from the Center for Disease Control and Prevention’s Wide-Ranging Online Data for Epidemiologic Research database to examine COVID-19 mortality among US patients with cancer and the general population from March 1, 2020, to May 31, 2022. Importance With the ongoing relaxation of guidelines to prevent COVID-19 transmission, particularly in hospital settings, medically vulnerable groups, such as patients with cancer, may experience a disparate burden of COVID-19 mortality compared with the general population. Shared Decision Making and Communication.Scientific Discovery and the Future of Medicine.Health Care Economics, Insurance, Payment.Clinical Implications of Basic Neuroscience.Challenges in Clinical Electrocardiography.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |